Jiaxi Song - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Jiaxi Song

Showing results (51-60 of 60) with videos related to

Pageof 6

Sort By:

You have reached the last page of results.This site can display upto 60 results.

Nature Communications|September 18, 2021

METTL3-mediated m6A RNA methylation promotes the anti-tumour immunity of natural killer cellsHao Song, Jiaxi Song, Ming Cheng, et al.

Oncotarget|June 2, 2016

Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinomaXiaoen Wang, Nicolas Solban, Prateek Khanna, et al.

Clinical Genitourinary Cancer|April 3, 2016

Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell CarcinomaKathleen M Mahoney, Susanna Jacobus, Rupal S Bhatt, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2015

Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal CancerLiang Zhang, Xiaoen Wang, Andrea J Bullock, et al.

Cancer Immunology Research|May 28, 2015

Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell CarcinomaMarcella Callea, Laurence Albiges, Mamta Gupta, et al.

Journal for Immunotherapy of Cancer|March 14, 2015

Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker studyAndré P Fay, Sabina Signoretti, Marcella Callea, et al.

Science Translational Medicine|July 14, 2017

HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferaseAbhishek A Chakraborty, Eijiro Nakamura, Jun Qi, et al.

Cancer Cell|August 14, 2014

Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressorGang Lu, Qing Zhang, Ying Huang, et al.

Cell|November 12, 2013

Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumorsBrooke M Emerling, Jonathan B Hurov, George Poulogiannis, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2016

Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell CarcinomaDavid J Kwiatkowski, Toni K Choueiri, André P Fay, et al.

Pageof 6

Search research articles

Showing results (51-60 of 60) with videos related to

Sort By:

Pageof 6

You have reached the last page of results.This site can display upto 60 results.

Nature Communications|September 18, 2021

METTL3-mediated m6A RNA methylation promotes the anti-tumour immunity of natural killer cellsHao Song, Jiaxi Song, Ming Cheng, et al.

Oncotarget|June 2, 2016

Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinomaXiaoen Wang, Nicolas Solban, Prateek Khanna, et al.

Clinical Genitourinary Cancer|April 3, 2016

Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell CarcinomaKathleen M Mahoney, Susanna Jacobus, Rupal S Bhatt, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2015

Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal CancerLiang Zhang, Xiaoen Wang, Andrea J Bullock, et al.

Cancer Immunology Research|May 28, 2015

Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell CarcinomaMarcella Callea, Laurence Albiges, Mamta Gupta, et al.

Journal for Immunotherapy of Cancer|March 14, 2015

Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker studyAndré P Fay, Sabina Signoretti, Marcella Callea, et al.

Science Translational Medicine|July 14, 2017

HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferaseAbhishek A Chakraborty, Eijiro Nakamura, Jun Qi, et al.

Cancer Cell|August 14, 2014

Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressorGang Lu, Qing Zhang, Ying Huang, et al.

Cell|November 12, 2013

Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumorsBrooke M Emerling, Jonathan B Hurov, George Poulogiannis, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2016

Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell CarcinomaDavid J Kwiatkowski, Toni K Choueiri, André P Fay, et al.

Pageof 6